• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Rapamycin Reduces Brain Hyperexcitability Driven by Activating AKT3 Mutation in Models

by
November 20, 2026
in Health
Reading Time: 3 mins read
0
Rapamycin Reduces Brain Hyperexcitability Driven by Activating AKT3 Mutation in Models

Rapamycin Reduces Brain Hyperexcitability Driven by Activating AKT3 Mutation in Models

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In complementary human cellular and mouse models, pharmacological inhibition with rapamycin reduced neuronal hyperexcitability and increased seizure thresholds linked to an activating genetic variant in AKT3, according to findings published in the Orphanet Journal of Rare Diseases. The investigation focused on understanding the downstream mechanisms that trigger intractable epilepsy and megalencephaly when AKT serine/threonine kinase 3 is pathologically activated.

AKT serine/threonine kinase 3 is abundantly expressed in the brain, where activating variants lead to cortical malformations and severe megalencephaly commonly accompanied by treatment-resistant seizures. While the upstream AKT inhibitor capivasertib offers a potential targeted approach, its long-term clinical utility starting in early infancy remains constrained by adverse effects. This therapeutic limitation created an urgent requirement to identify safer downstream intervention targets within the phosphoinositide 3-kinase–AKT–mTOR signaling cascade.

To investigate these pathogenic mechanisms and evaluate potential therapeutic responses, investigators established both in vitro and in vivo disease models based on a specific heterozygous AKT3 variant, NM_005465.7:c.233 A > G (p.Q78R), identified in a patient exhibiting cortical malformations and megalencephaly. The research team generated patient-derived induced pluripotent stem cells and created isogenic control lines utilizing CRISPR/Cas9 genome-editing technology.

Following genome editing, the patient-derived stem cells and their isogenic controls were differentiated into glutamatergic neurons. In parallel, researchers established a genome-edited mouse model carrying the identical AKT3 p.Q78R variant. These dual systems allowed the team to systematically compare cellular alterations and evaluate organism-level functional vulnerabilities against control benchmarks.

At the cellular level, the patient-derived glutamatergic neurons demonstrated notable somatic enlargement alongside elevated activity of mechanistic target of rapamycin complex 1 (mTORC1).

Transcriptomic profiling revealed that the patient-derived neurons underwent differentiation and maturation comparable to control cells, confirming that basic developmental staging remained intact. However, the analysis uncovered distinct gene expression alterations in the mutated lines, including the dysregulation of protocadherin family genes that are functionally implicated in synaptogenesis and neuronal connectivity.

The corresponding genome-edited mouse model carrying the AKT3 variant exhibited megalencephaly, marked neuronal hypertrophy, and reduced overall survival. When exposed to chemical convulsants, these mice displayed a decreased latency to chemically-induced seizures, demonstrating in vivo vulnerability to epileptogenic activity that parallels the clinical phenotype.

Administration of the mTOR inhibitor rapamycin directly counteracted these pathological features across both experimental systems.

The authors concluded that the shared cellular and behavioral rescue across human and rodent models supports targeting downstream components of the phosphoinositide 3-kinase–AKT–mTOR pathway. This pharmacological consistency provides a rational therapeutic strategy for managing intractable epilepsy driven by activating AKT3 variants.

Because adverse effects limit the long-term use of capivasertib from infancy, identifying safer downstream interventions within the phosphoinositide 3-kinase–AKT–mTOR pathway represents an important step toward targeted therapeutic strategies for AKT3-related epilepsy.

Subject of Research: Pharmacological rescue of AKT3-driven neuronal hyperexcitability and seizures using rapamycin

Article Title: Rapamycin rescues neuronal hyperexcitability and seizures driven by megalencephaly-causing AKT3 activation

Article References: Miyamoto, Y., Mori, T., Ishikawa, M., Ichise, E., Suzuki, Y., Furukawa, Y., Matsuura, A., Yamashita, S., Tozawa, T., Hasegawa, T., Morimoto, M., Iehara, T., Okano, H., Hayashi, S., & Chiyonobu, T. (2026). Rapamycin rescues neuronal hyperexcitability and seizures driven by megalencephaly-causing AKT3 activation. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-026-04684-w

Image Credits: AI Generated

DOI: 10.1186/s13023-026-04684-w

Keywords: AKT3, Rapamycin, mTORC1, Megalencephaly, Intractable Epilepsy, Neuronal Hyperexcitability, Cortical Malformations, Glutamatergic Neurons, CRISPR/Cas9, Induced Pluripotent Stem Cells, Mouse Models, Protocadherins, Capivasertib, PI3K-AKT-mTOR Pathway, Synaptogenesis, Seizure Threshold

News Source: Cassandra Pierce. (November 20, 2026). Rapamycin Reduces Brain Hyperexcitability Driven by Activating AKT3 Mutation in Models. Scienmag.

Tags: AKT3capivasertibCortical MalformationsCRISPR-Cas9glutamatergic neuronsinduced pluripotent stem cellsIntractable Epilepsymegalencephalymouse modelsmTORC1neuronal hyperexcitabilityPI3K-Akt-mTOR pathwayProtocadherinsRapamycinseizure thresholdsynaptogenesis
Share12Tweet7Share2ShareShareShare1

Related Posts

Frequent Social Media Use Linked to Depression and Anxiety in Egyptian University Staff

Frequent Social Media Use Linked to Depression and Anxiety in Egyptian University Staff

November 20, 2026
Many Youth Seeking Obesity Treatment Report Moderate to Severe Pain

Many Youth Seeking Obesity Treatment Report Moderate to Severe Pain

November 20, 2026

Pediatric Acute Promyelocytic Leukemia Series Evaluates Outcomes and Intensive Care Needs

November 20, 2026

School WASH Programs Improve Knowledge and Facilities but Fail Behavior Change

November 20, 2026

POPULAR NEWS

  • Wild Custard Apple Leaf Size and Chemistry Vary Across Ghana Ecologies

    Wild Custard Apple Leaf Size and Chemistry Vary Across Ghana Ecologies

    29 shares
    Share 12 Tweet 7
  • Zanubrutinib Outperforms Older BTK Inhibitors in B Cell Lymphoma Meta-Analysis

    29 shares
    Share 12 Tweet 7
  • Child Care Pressures Spur Female Entrepreneurship Across Urban China via Reduced Compensation

    29 shares
    Share 12 Tweet 7
  • Pandemic Widened Physical Health Gap Between High and Low Earners in Germany

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Creep Model Simulates Sustained Deformation in South China Sea Hydrate Sediments

Frequent Social Media Use Linked to Depression and Anxiety in Egyptian University Staff

Industrial Solid Wastes Yield Resilient Glass-Ceramics That Immobilize Heavy Metals

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.